Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Biography

Rory Collins studied Medicine at St Thomas’s Hospital Medical School, London, and Statistics at George Washington University and Oxford University.

He came to Oxford in 1981 to run the ISIS “mega-trials” which showed that emergency treatment of heart attacks with streptokinase and aspirin halves mortality. Subsequently, his focus has involved showing that lowering LDL-cholesterol safely reduces the risk of having heart attacks and strokes.

In 1985, he became co-director (with Richard Peto) of the University of Oxford's Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU). He was appointed BHF Professor of Medicine and Epidemiology in 1996, and Head of the Nuffield Department of Population Health in 2013.

Rory became Principal Investigator of the UK Biobank prospective study of 500,000 people in 2005. He was elected to the Fellowship of the UK Academy of Medical Science in 2004 and the Royal Society in 2015, and knighted by the Queen for services to Science in 2011.

Forthcoming events

Title TBC

Monday, 15 April 2024, 1pm to 2pm @ BDI/OxPop Building LG seminar rooms

The effects of BCG on non-specific resistance to respiratory infection

Monday, 13 May 2024, 1pm to 2pm @ BDI/OxPop Building LG seminar rooms

Title TBC

Monday, 20 May 2024, 1pm to 2pm @ BDI/OxPop Building LG seminar rooms